ONCOLOGY Vol 25 No 3 | Oncology

Does Evidence-Based Medicine Really Reduce Costs?

March 16, 2011

Emerging as one of the many pieces to the puzzle is the adoption of pathways based on evidence-based medicine (EBM). It has long been theorized that the use of standardized care models not only improves the quality of care, but also reduces costs and makes costs more predictable.

Have We Made Progress in Inflammatory Breast Cancer? Not So Fast

March 21, 2011

Breast cancer has long been described as a very heterogeneous disease, and clinicians have struggled with identifying the appropriate treatment program for an individual patient on the basis of multiple variables, including histology, nuclear grade, tumor size, nodal status, hormone receptor status, and a variety of prognostic factors.

Inflammatory Breast Cancer: the Road to Progress

March 21, 2011

Drs. Dawood and Cristofanilli provide a concise review of inflammatory breast cancer (IBC) and succinctly cover its most salient features, including its clinicopathologic characteristics, its key molecular features, and an overview of treatment outcomes.

What Is the Indication for Sorafenib in Hepatocellular Carcinoma? A Clinical Challenge

March 15, 2011

In this review article we will discuss the current data on, and future role of, sorafenib in the treatment of hepatocellular carcinoma beyond Child-Pugh A cirrhosis, in conjunction with local therapy, and in a transplant setting.

Immunotherapy in Castration-Resistant Prostate Cancer: Integrating Sipuleucel-T Into Our Current Treatment Paradigm

March 15, 2011

Prostate cancer is the second-leading cause of death in men in the United States; more than 217,730 new cases were expected to be diagnosed in 2010.[1] Although the majority of patients with advanced prostate cancer have an initial response to androgen deprivation, essentially all patients eventually progress to a castration-resistant state, manifested by rising levels of prostate-specific antigen (PSA),

Epigenetics in Cancer: What's the Future?

March 15, 2011

The understanding that epigenetic changes are prevalent in cancer and play a causative role in its biology has led to the development of new therapeutic approaches that target the epigenetic machinery.

Inflammatory Breast Cancer: What Progress Have We Made?

March 15, 2011

Over the past decade, inflammatory breast cancer (IBC), a rare and aggressive subtype of locally advanced breast cancer (LABC), has received much attention at the level of public awareness as well as at the level of research.